OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy for use in applications requiring partial bone replacement, without the need for secondary interventions.
The therapy uses autologous blood in order to create a clot in the OR. The blood is injected with bone morphogenetic protein-6 (BMP-6) and applied where new bone is required. New bone is formed within several months, requiring just a deciliter of blood to create the clot.
The therapy is expected to have application in the treatment of acute radius fractures and recalcitrant non-unions of the tibia.
Phase 2 clinical trials are underway in Croatia, Sarajevo and Vienna, including use in spinal fusion. By the end of the trials, 75 patients will have undergone treatment.
The OSTEOGROW project is due to finish in December 2016. Researchers are now concentrating on commercial prospects for the new treatment.
OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy for use in applications requiring partial bone replacement, without the need for secondary interventions.
The therapy uses autologous blood in order to create a clot in the OR. The blood is injected with bone morphogenetic protein-6 (BMP-6)...
OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy for use in applications requiring partial bone replacement, without the need for secondary interventions.
The therapy uses autologous blood in order to create a clot in the OR. The blood is injected with bone morphogenetic protein-6 (BMP-6) and applied where new bone is required. New bone is formed within several months, requiring just a deciliter of blood to create the clot.
The therapy is expected to have application in the treatment of acute radius fractures and recalcitrant non-unions of the tibia.
Phase 2 clinical trials are underway in Croatia, Sarajevo and Vienna, including use in spinal fusion. By the end of the trials, 75 patients will have undergone treatment.
The OSTEOGROW project is due to finish in December 2016. Researchers are now concentrating on commercial prospects for the new treatment.
Copy to clipboard 
